National systemic lupus erythematosus prospective cohort in Saudi Arabia
A study protocol

Ibrahim A. Almaghlouth, MD, MSc\textsuperscript{a,b,*}, Lena M. Hassen, PhD\textsuperscript{a,c}, Hana S. Alahmari, MD\textsuperscript{a,d},
Asma Bedaiwi, MD\textsuperscript{a}, Rana Albarrak, MD\textsuperscript{a}, Maha Daghestani, PhD\textsuperscript{a}, Eman Alqurtas, MD\textsuperscript{a},
Abdulaziz Alkhalaf, MD\textsuperscript{a}, Mohammed Bedaiwi, MD\textsuperscript{a}, Mohammed Omair, MD\textsuperscript{a}, Sultan Almogairen, MD\textsuperscript{a},
Hussein Alarfaj, MD\textsuperscript{a}, Abdulrahman Alarfaj, MD\textsuperscript{a}

Abstract
Systemic Lupus erythematosus (SLE) is a chronic multisystem, multifactorial inflammatory autoimmune disease. The SLE patients have 3 times increased risk of mortality based on international data with ethnicity playing an important impact on patients’ morbidity and mortality. Descriptive studies from Saudi Arabia showed variation in clinical features from one region to another. Moreover, reliable inference from these studies is limited by study methodology and lack of translational data using biological samples to understand clinical phenotypes of Saudi SLE patients.

The aim of this report is to describe the prospective study protocol of the National Systemic Lupus Erythematosus Cohort in Saudi Arabia. The purpose of this cohort study is multifold: first, to examine clinical characteristics and molecular phenotypes of Saudi SLE patients in relation to local environment and practices/lifestyles; second, to assess long-term outcomes of SLE in Saudi population and factors that influence favorable outcomes; third, to compare the effectiveness of various treatment regimens in Saudi SLE population.

This study is a longitudinal prospective cohort study of adult, Saudi SLE patients using open cohort study design. Primary outcomes include disease-related outcomes (activity, improvement, and organ damage) and patient-reported outcomes (quality of life). Secondary outcomes include physiological and molecular modifications associated with changes in disease activity states. Results and analysis are in on-going study.

This study provides a source of reliable data for clinical and translational research. This will allow us to have a holistic approach to SLE pathogenesis especially in Saudi population and may take us a step further toward much more personalized medicine.

This protocol has been registered in NIH ClinicalTrial.gov (ClinicalTrial.gov identifier: NCT04604990) on October 27, 2020.

Abbreviations: ACR = American College of Rheumatology, DMARD = disease-modifying anti-rheumatic drugs, IRB = institutional review board, KKUH = King Khalid University Hospital, KSU = King Saud University, LupusQoL = Lupus Quality of Life, SLE = systemic lupus erythematosus, SLICC = Systemic Lupus International Collaborating Clinics, SLICC/ACR-DI = SLICC/ACR Damage Index, SPSS = Statistical Package for the Social Sciences, SRI-50 = SLEDAI-2K Responder Index, SPIRIT = Standard Protocol Items: Recommendations for Interventional Trails.

Keywords: cohort, lupus, observational, outcomes, phenotypes, Saudi Arabia
1. Introduction

1.1. Background

Systemic lupus erythematosus (SLE) is a chronic multisystem disease in which an underlying aberrant immune system leads to inflammation in various organs, and possibly consequent damage.\[1]\] Incidence and prevalence of the disease vary significantly from 1 to 7 per 10,000 patients to 19 to 159 per 10,000 patients, respectively, in the United States.\[2\] The estimated incidence in the United Arab Emirates is around 3.5 per 100,000 patients and the prevalence is 109 per 100,000 patients\[3\], while in Saudi Arabia the prevalence is around 19 per 100,000 patients.\[4\] Such variation is likely due to the use of different definitions, studies' standardization of age, and racial background.\[4\]

Ethnicity is an important variable in disease occurrence, severity, phenotypic presentation, and prognosis.\[5\] For example, patients with African, Hispanic, and Native American tend to have more severe disease and, consequently, increased mortality.\[5-7\] Unfortunately, national Saudi studies in SLE are sporadic and limited in addressing our unique population in a prospective standardized fashion. The majority of the studies use retrospective chart review-based designs that are threatened by potential selection and information biases. They also lack molecular and genetic data of Saudi patients with SLE. As a result, our understanding of Saudi SLE patients is limited.

Thus, our national lupus registry protocol aims to establish an extensive record of well-characterized SLE patients in Saudi population on which to develop consistent longitudinal studies. This will provide a better understanding of disease characteristics and progression in Saudi population coupled with molecular data, and, sanguinely, be a fundamental attribution for future clinical trials in Saudi Arabia.

1.2. Objectives

The main objectives of this cohort are to:

- examine the changing trends in SLE disease outcomes (activity, severity, improvement, organ-damage, mortality) and patient-reported outcomes (quality of life) over time.
- evaluate the effect of risk factors (sociodemographic, environmental, social, family, and medical histories) on disease related outcomes including disease activity and disease damage.
- investigate laboratory characteristics including molecular signatures (genetic, epigenetic, genomic, immunologic, microbiotic) to identify novel mendelian genotypes/phenotypes.
- explore drug adherence, response, side effects, and associated molecular signature profile (pharmacometabolomics).
- establish a baseline Saudi polygenic risk score and compare it to Caucasian risk score in relation of clinical and laboratory characteristics.

2. Methods

2.1. Participants, interventions, and outcomes

2.1.1. Study design and setting. This is a prospective, cohort study. (The study was initiated in November 2019 and follows an open observational registry). This study design was guided by Standard Protocol Items: Recommendations for Interventional Trails (SPIRIT) checklist.\[8,9\]

2.1.2. Participant recruitment. Participants are recruited from both the General and Specialized Rheumatology Clinic at King Khalid University Hospital (KKUH) in King Saud University (KSU). Referred patients from other clinics from inside or outside KKUH are also allowed. Collaboration with other local and international centres is planned in the first 5 years of the study.

2.1.3. Eligibility criteria. Patients who met the inclusion criteria are enrolled after obtaining informed consent. Inclusion criteria: patients must be Saudi (or Arab living in Saudi Arabia are also allowed), adult (over 18 years old) and diagnosed with lupus according to the classification criteria of American College of Rheumatology (ACR),\[10\] Systemic Lupus International Collaborating Clinics (SLICC)\[11\] or ACR/European League Against Rheumatism \[12\], irrespective of diagnosis date or treatment plan allowing for both prevalence and inception cohort components. Exclusion criteria: patients who do not fulfil the aforementioned criteria.

2.1.4. Sample size. The expected sample size is estimated to be about 1000 patients. Sample size was calculated based on the following assumptions: SLE prevalence of 19.28 per 100,000\[4\] and population size of 13,147,004 Saudis aged 18 years and older (according to the Saudi Arabian 2016 Census issued by General Authority of Statistics), with confidence interval of 95%, and precision of 5%.

2.1.5. Patient cohort division. Consented patients who fulfill the SLE classification criteria are categorized as inception new (<24 months from the onset of their symptoms) and prevalent (>24 months) patients. First visit is considered the baseline visit and subsequent visits are considered follow-up visits (see Fig. 1). Each patient has a standard follow-up visit every 3 months unless otherwise clinically indicated. Research assistants ensure patients follow protocol including attending visits and survey completion. Any missed follow-ups are handled by direct communication with patients (phone or email) to reschedule visits or investigate reasons for withdrawal.

2.1.6. Exposure.

- Sociodemographic information (age, gender, nationality, marital status, education level, employment, income, residency region).

Figure 1. Timeline of enrollment and visits for participants. m = months(s).
Patient and family medical history (autoimmunity including SLE, other seropositive diseases, hospitalization, and pregnancy).

Environmental factors (smoke inhalation, smoking, sun exposure, fasting, physical activity, alcohol consumption, medication- or environmental-related allergy).

Infections including but not limited to bacterial (Mycobacterium tuberculosis, Clostridium difficile, Helicobacter pylori), viral (Hepatitis B, Hepatitis C, Human immunodeficiency, Cytomegalovirus, Epstein-Barr, Herpes simplex, Varicella-zoster), fungal (Candida albicans, Pneumocystis jiroveci), and protozoal.

Medications (monotherapy or combination therapy) including conventional immunosuppressive disease-modifying anti-rheumatic drugs (DMARD), conventional non-immunosuppressive DMARD, targeted biologic DMARD, targeted synthetic DMARD, nonsteroidal anti-inflammatory drug, steroid, supplements, other medications used for other comorbidities.

### 2.1.7. Primary outcomes.

Clinical outcomes:

- SLE disease activity measured using SLE Disease Activity Index 2000 (SLEDAI-2K).[13,14]
- SLE Disease improvement using SLEDAI-2K Responder Index (SRI-50).[15]
- Disease-related damage measured using SLICC/ACR Damage Index (SLICC/ACR-DI).[16]

Patient-reported outcomes:

- SLE-related quality of life measured using Lupus Quality of Life (LupusQoL).[17]
- Patient-reported outcomes measured using Patient-Reported Outcomes Measurement Information System 29-item (PROMIS-29) profile version 2.1.[18]

### 2.1.8. Secondary outcomes.

The following items are investigated according to patient’s clinical indication:

- Cardiovascular/circulatory system
  - Percutaneous coronary intervention, myocardial infarction, stent thrombosis, target vessel lesion revascularizations, stroke, and death as a measure of Major Adverse Cardiovascular Event via patient history and monitoring heart-related failure hospitalizations.
  - Subclinical atherosclerosis: all patients will have a baseline electrocardiogram and echocardiogram. Those with abnormalities will be subjected to further investigations as clinically indicated. Random patients will be selected for image specific substudies that aim to identify subclinical atherosclerosis. Patients enrolled in these substudies will have baseline imaging and at 2 years interval for 6 years. Data will be collected using image-specific case report form. Images modalities include carotid artery intimal thickness, plaques size, ankle-brachial index as measure of peripheral artery disease using color duplex tomography for calcium score.

- Digestive system
  - Gastrointestinal disorders confirmed using abdomen ultrasound, gastroendoscopy, manometry, or colonoscopy as clinically indicated.

- Integumentary system/skin
  - Cutaneous Lupus Erythematosus disease activity and damage using Cutaneous Lupus Erythematosus Disease Area and Severity Index (C-LADESI) index will be used if skin is affected.

### 2.1.9. Biological specimens.

- Blood: venous blood (20mL) is collected from each patient by the phlebotomist or assigned nurse and handled according to routine phlebotomy techniques followed at KKUH. For immunologic analysis; serum is separated from SST tube, then transferred into aliquots and stored at −80°C until analysis. For proteomic analysis; plasma is separated from EDTA tube, transferred into aliquots and stored at −80°C until analysis. For genomic DNA analysis;uffy coat is isolated from EDTA tube, transferred into aliquots and stored at −80°C until analysis. For RNA analysis; blood is directly collected into PAXgene Blood RNA tube and stored at −80°C until analysis.

- Excreta: Patient self-collected fresh stool (15 mg) and urine (5 mL) is obtained from each patient into sterile containers and stored at −80°C for microbiome analysis.

All collected biological specimens are transported to the Core Lab at the College of Medicine Research Center in KSU where they are prepared. Samples are then transferred to the College of Medicine Biobank where they are stored indefinitely and/or processed for current or ancillary studies in the future. All biosamples are maintained using sample identification labels that contain protocol ID, patient unique research ID, initials of derived sample type and collected tube, aliquot number, time and date of collection. All biosamples and related data are stored securely in soft and hard copies, while the key for patient’s identification is kept with the principal investigator.

### 2.2. Data collection, management, and analysis

#### 2.2.1. Data collection schedule.

Patients are examined by the attending physician and treated with a standard of care as determined by the standardized clinical care procedures followed at KKUH. After a patient’s initial visit (baseline), follow-up visits...
are divided into short (follow-up) and long (annual) visits. Schedule of data collection for variables is shown in Table 1.

### 2.2.2. Data management.
Data is collected by trained clinic staff (physician and/or nurse) according to the standard operating procedure for data entry in each clinical visit. Case report forms and surveys for data collection are built using Research Electronic Data Capture [28] hosted by KSU. A copy of the data dictionary is provided (see Supplemental Material, http://links.lww.com/MD/G297). Then, all data is transferred and stored into Caisis-KSU innovation hub, a data manager program, based at the Deanship of Electronic Communication at KSU. Entered data undergo validation and quality checks on quarterly basis prior to exporting data.

Database is governed by the protocol committee members consisting of principal investigator and coinvestigator. The principal investigator has full access and the key for patient consisting of principal investigator and coinvestigator. The exporting data. Validation and quality checks on quarterly basis prior to exporting data.

### 2.2.3. Statistical methods.
The data collected in this study is a longitudinal-type data which lists completed and missed data. Missed data may include complete random, random, and nonrandom deletions. Loss of data will be accounted and analyzed for impact on outcome variables accordingly. Multiple imputation will be used to account for missing data as appropriate.

For descriptive statistics, qualitative data will be described using frequency tables and percentages, while quantitative data will be described using mean, standard deviation, median, and lower and upper quartiles. Parametric and nonparametric tests will be used to assess continuous variables for significance differences between groups. A Student t test and Pearson χ² show presence of correlation among variables. Univariate and multivariate logistic and linear regression models will be used to examine the association between exposure and outcome variables and identify independent predictors of outcomes.

The hypothesis test will be a 5% of a 2-sided significance expressed with 95% confidence intervals. A P value of less than .05 will be considered statistically significant. All analyses will be performed using Statistical Package for the Social Sciences (SPSS) version 25.0 (IBM Inc, Armonk, NY).

### 2.3. Ethics and dissemination

#### 2.3.1. Research ethics.
Research ethical approval for this study was obtained from the Institutional Review Board (IRB) of KSU in Riyadh, Saudi Arabia (IRB approval no. E-19-3955/58) and was registered in ClinicalTrial.gov (ClinicalTrial.gov identifier: NCT04604990).

#### 2.3.2. Protocol amendment.
Any modifications to the protocol will be communicated to relevant parties.

#### 2.3.3. Consent.
This study is carried out in accordance with the principles of the Declaration of Helsinki set forth by the World Medical Association. All informed, assented patients are enrolled using a signed written consent form according to IRB of KSU guidelines.

#### 2.3.4. Data availability.
The data repository generated during the study are not publicly available due to IRB restrictions. However, analyzed datasets that support study findings will be available upon publication from the corresponding author on reasonable request.

### 3. Discussion

Our current understanding of SLE has been fostered by ongoing efforts of long-term observational cohorts, such as John Hopkins University and University of Toronto lupus cohorts, that have enriched our knowledge of disease presentation, course, and outcomes. These cohorts serve as exemplary models and stand at the cornerstones of many SLE studies, such as investigation of disease manifestations, organ-specific outcomes, prognosis, risk factor, clinical–laboratory correlations, and therapeutic efficacy and tolerability studies that promote a deeper understanding of disease behavior.[29,30]

The SLICC group is, also, no stranger to this effort, where it has taken up the challenge of putting together standardized clinical assessments and indices used by rheumatologists worldwide today,[14–16,31] as well as establishing International Inception Cohort by recruiting real-world data regarding the outcomes of atherosclerosis, nervous system, lupus nephritis, and metabolic involvement in SLE.

Although these studies have contributed much insight into the disease as we know it, more are necessary to fill our knowledge gap regarding descriptive clinical characteristics, qualitative-type research of patient-related outcomes, genotype-phenotype correlation, and pharmacometabolomics in Saudi patients.

The current nature of SLE highlights the importance of a multidimensional approach to assess the disease. Translational research suggests that when pathophysiological factors related to disease outcomes have been managed, genomic approaches may be a worthwhile path of study to integrate novel therapeutic

### Table 1

| Variables/visits | Baseline (w/in 1 m) | Follow-up (3 m ± 2 w) | Follow-up (6 m ± 2 w) | Follow-up (9 m ± 2 w) | Annual (12 m ± 2 w) |
|------------------|---------------------|------------------------|-----------------------|------------------------|---------------------|
| Informed consent | ✔                   | ✓                      | ✓                     | ✓                      | ✓                   |
| Demographic and medical history | ✔ | ✔ | ✓ | ✓ | ✓ |
| Biological specimens | ✔ | ✔ | ✓ | ✓ | ✓ |
| SLE classification criteria | ✔ | ✔ | ✓ | ✓ | ✓ |
| Physiological status | ✔ | ✔ | ✓ | ✓ | ✓ |
| Clinical outcome assessments | ✔ | ✔ | ✓ | ✓ | ✓ |
| PRO questionnaire | ✔ | ✔ | ✓ | ✓ | ✓ |
| Medications and adherence scale | ✔ | ✔ | ✓ | ✓ | ✓ |
| Labs and images (±1 m accepted) | S & L | S | S | S | L |

L = long (annual) protocol, m = month(s), PRO = patient-reported outcome, S = short (follow-up) protocol, SLE = systemic lupus erythematosus, w = week(s), y = year(s).
regimens effective for patient populations. For instance, researchers have proved the usefulness of genetic analysis in predicting flare in SLE. [32] The results showed that patients who had a higher interferon-regulated gene expression profile had a higher level of disease activity at the time of the study. Thus, utilizing such robust demonstration in disease detection and control is perhaps a promising avenue worth venturing in cohorts.

Although evidence of ethnicity has shown to be an important factor of disease outcome in SLE patients, a fair representation of Middle Eastern or Arabs remains scarce. Thus, extrapolated data from international cohorts are often generalized to all SLE patients. This evokes the importance of establishing longitudinal cohorts encompassing these ethnicities.

Additionally, SLE disease in Saudi Arabia has yet to be well defined, especially in a population with high consanguinity and high inbreeding coefficient. [131] Until now, there has been no prospective cohort study for SLE patients in Saudi Arabia. As a result, the current published literature is focused on retrospective chart reviews which are subjected to many forms of bias. [6,34]

Thus, these studies are difficult to utilize for translational research because clinical data are not complemented by simultaneously collected biological data. [35]

The importance of a national prospective cohort study to address the aforementioned knowledge gaps is high, especially in the context of assessing the burden of long-term outcomes and growing national interest in drug development programs, in the current time.

Acknowledgments

The authors acknowledge all their collaborators, especially the Toronto Lupus Cohort for their support, the College of Medicine Research Center at King Saud University for providing a start-up fund as well administrative support for the cohort study. Also, special thanks to Dr Huda Alfaris, Dr Alaa Alsawi, and all the Rheumatology Unit staff at King Saud University Hospital for piloting the study protocol.

Author contributions

Ibrahim A. Almaghlouth and Lena M. Hassen equally contributed to study protocol design. Hana Alahmari, Asma Bedaiwi, Rana Albarrak piloted study protocol plan. Maha Daghestani, Eman Alqurtas, Abdulaziz Alkhalaf, Mohammed Bedaiwi, Mohammed A Omair, Sultan M Almogairen, Hussein F Alarfaj, Abdulrahman S Alarfaj reviewed study protocol manuscript. Conceptualization: Ibrahim A Almaghlouth, Lena M Hassen. Data curation: Ibrahim A Almaghlouth, Lena M Hassen. Formal analysis: Ibrahim A Almaghlouth, Lena M Hassen. Funding acquisition: Ibrahim A Almaghlouth, Lena M Hassen. Investigation: Ibrahim A Almaghlouth, Lena M Hassen. Methodology: Ibrahim A Almaghlouth, Lena M Hassen. Project administration: Ibrahim A Almaghlouth, Lena M Hassen, Hana S Alahmari, Asma A Bedaiwi, Rana A Albarrak. Resources: Ibrahim A Almaghlouth, Lena M Hassen. Software: Ibrahim A Almaghlouth, Lena M Hassen. Supervision: Ibrahim A Almaghlouth, Lena M Hassen. Validation: Ibrahim A Almaghlouth, Lena M Hassen. Visualization: Ibrahim A Almaghlouth, Lena M Hassen.

Writing – original draft: Ibrahim A Almaghlouth, Lena M Hassen, Hana S Alahmari, Asma A Bedaiwi, Rana A Albarrak.

Writing – review & editing: Ibrahim A Almaghlouth, Lena M Hassen, Maha H Daghestani, Eman M Alqurtas, Abdulaziz T Alkhalaf, Mohammed K Bedaiwi, Mohammed A Omair, Sultan M Almogairen, Hussein F Alarfaj, Abdulrahman S Alarfaj.

References

[1] Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365:2110–21.

[2] Pons-Estel GJ, Alarcón GS, Scofield L, Reinilb L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257–68.

[3] Al Dhanhani AM, Agarwal M, Othman YS, Bakoush O. Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE. Lupus 2017;26:664–6.

[4] Al-Arfaj AS, Al-Balla SR, Al-Dalaan AN, et al. Prevalence of systemic lupus erythematosus in central Saudi Arabia. Saudi Med J 2002;23:87–9.

[5] Fletcher RH, Fletcher SW, Fletcher GS. Clinical epidemiology: the essentials. 5th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2014. pp. 253.

[6] Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002;359:248–52.

[7] Relton C, Torgerston D, O’Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ 2010;340:c1066.

[8] Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7.

[9] Chan AW, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. Published 2013 Jan 8.

[10] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

[11] Petri M, Orbaei AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.

[12] Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71:1400–12.

[13] Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630–40.

[14] Gladman DD, Ibáñez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.

[15] Touma Z, Gladman DD, Ibáñez D, Urowitz MB. SLEDAI-2K responder index 50 captures 50% improvement in disease activity over 10 years. Lupus 2012;21:1305–11.

[16] Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.

[17] McElhone K, Abbondanzero J, Schelmerding J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007; 57:972–9.

[18] El Miedany Y, El Gaafary M, Sayed S, Ahmed I. THU0037 validation of the montreal cognitive assessment test: a useful tool in screening of cognitive impairment in patients with systemic lupus erythematosus. J Clin Rheumatol 2012;18:325–38.
[21] Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954–60.

[22] Ceccarelli F, Perricone G, Massaro L, et al. The role of disease activity score 28 in the evaluation of articular involvement in systemic lupus erythematosus. ScientificWorldJournal 2014;2014:236842.

[23] Kanis JA on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. London (UK): 2007. Available at: http://www.shef.ac.uk/FRAX. Accessed December 1, 2019.

[24] Watts NG, Leslie WD, Foldes AJ, et al. 2013 International Society of Clinical Densitometry Position Development Conference: task force on normative database. J Clin Dentom 2013;16:472–81.

[25] Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5.

[26] Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000;42:241–7.

[27] Hassen LM, Almaghlouth IA, Hassen IM, et al. Impact of COVID-19 outbreak on rheumatic patients’ perceptions and behaviors: a cross-sectional study. Int J Rheum Dis 2020;23:1541–9.

[28] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.

[29] Fangham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep 2013;15:360.

[30] Urowitz MB, Gladman DD. Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience. Rheum Dis Clin North Am 2005;31:211–21.

[31] Legge A, Kirkland S, Rockwood K, et al. Construction of a frailty index as a novel health measure in systemic lupus erythematosus. J Rheumatol 2020;47:72–81.

[32] Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610–5.

[33] al Husain M, al Bunyan M. Consanguineous marriages in a Saudi population and the effect of inbreeding on prenatal and postnatal mortality. Ann Trop Paediatr 1997;17:155–60.

[34] Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community Health 2004;58:635–41.

[35] Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol 2010;63:64–74.